GlobeNewswire
Dublin, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The "Gastroparesis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. Gastroparesis - Epidemiology Forecast to 2030 delivers an in-depth understanding of the disease, historical and forecasted Gastroparesis epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Study Period: 2017-2030Epidemiology PerspectiveThe disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalence of Gastroparesis, Gender-specific Prevalence of Gastroparesis, Severity-specific Prevalence of Gastroparesis, Type-specific Prevalence of Gastroparesis and Total Diagnosed Prevalent Population of Gastroparesis a scenario of Gastroparesis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.Detailed Epidemiology Segmentation The total prevalent population of gastroparesis in the 7MM is expected to rise from 33,690,400 in 2017.As per estimates, the highest prevalence of gastroparesis was observed in the United States with 13,019,321 cases in 2017, which is likely to rise by 2030.As per the analysis, a higher percentage of prevalence was observed for females, in comparison to males, in all the 7MM countries.According to the analysis, it has been observed that mild cases are more prominent in comparison to moderate-to-severe. In the United States, 7,811,592 mild cases were observed in 2017, i.e., 60% of the gastroparesis patient pool. Additionally, moderate-to-severe accounted for 40% of the gastroparesis patient pool.Among the major types of gastroparesis, i.e., idiopathic, diabetic and post-surgical gastroparesis, idiopathic gastroparesis accounts for a higher number of gastroparesis cases.Among the EU5 countries, in 2017, Germany had the highest prevalent population of gastroparesis followed by Spain and Italy. On the other hand, the United Kingdom had the lowest prevalent population of Gastroparesis. Scope of the Report The report covers the descriptive overview of Gastroparesis, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.The report assesses the disease risk and burden and highlights the unmet needs of Gastroparesis.The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Gastroparesis, Total Diagnosed and Treated Cases of Gastroparesis. Key Questions Answered What is the disease risk, burden and unmet needs of Gastroparesis?What is the historical Gastroparesis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?What would be the forecasted patient pool of Gastroparesis at the 7MM level?What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Gastroparesis?Out of the countries mentioned above, which country would have the highest prevalent population of Gastroparesis during the forecast period (2020-2030)?At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)? Key Topics Covered 1 Key Insights2 Gastroparesis: Market Overview at a Glance2.1. Total Market Share (%) Distribution of Gastroparesis in 20172.2. Total Market Share (%) Distribution of Gastroparesis in 20303 Executive Summary4 SWOT Analysis5 Gastroparesis: Disease Background and Overview5.1 Introduction5.2 Types of Gastroparesis: Based on Causes5.2.1 Idiopathic Gastroparesis (IG)5.2.2 Diabetic Gastroparesis (DGp)5.2.3 Iatrogenic and Postsurgical Gastroparesis5.3 Clinical Signs and Symptoms5.4 Mechanisms or pathophysiology of gastroparesis5.5 Diagnosis of Gastroparesis6 Recognized Establishments7 Epidemiology and Patient Population7.1 Key Findings7.2 Epidemiology Methodology7.3 Total Prevalence of Gastroparesis in the 7MM7.4 Type-specific Prevalence of Gastroparesis in the 7MM7.5 Gender-specific Prevalence of Gastroparesis in the 7MM7.6 Severity-specific Prevalence of Gastroparesis in the 7MM7.7 Total Diagnosed Prevalent Population of Gastroparesis in the 7MM8 United States Epidemiology8.1 Assumptions and Rationale8.2 Total Prevalence of Gastroparesis in the United States8.3 Type-specific Prevalence of Gastroparesis in the United States8.4 Gender-specific Prevalence of Gastroparesis in the United States8.5 Severity-specific Prevalence of Gastroparesis in the United States8.6 Total Diagnosed Prevalence of Gastroparesis in the United States9 EU5 Epidemiology9.1 Germany Epidemiology9.2 France Epidemiology9.3 Italy Epidemiology9.4 Spain Epidemiology9.5 United Kingdom Epidemiology10 Japan10.1 Assumptions and Rationale10.2 Total Prevalence of Gastroparesis in Japan10.3 Type-specific Prevalence of Gastroparesis in Japan10.4 Gender-specific Prevalence of Gastroparesis in Japan10.5 Severity-specific Prevalence of Gastroparesis in Japan10.6 Total Diagnosed Prevalence of Gastroparesis in Japan For more information about this report visit https://www.researchandmarkets.com/r/atgajs Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900